热门资讯> 正文

Exact Sciences为其结直肠癌检测获得医疗保险

2025-07-09 21:14

Exact Sciences (NASDAQ:EXAS) has announced that its oncodetect test for detecting residual disease in colorectal cancer is now covered by Medicare.
This coverage is provided through the Centers for Medicare & Medicaid Services’ program for molecular diagnostics, allowing the test to be used repeatedly for patients with stage II, III, and resectable stage IV colorectal cancer during follow-up and monitoring over five years.

More on Exact Sciences

Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling
Exact Sciences Corporation 2025 Q1 - Results - Earnings Call Presentation
Exact Sciences Corporation (EXAS) Q1 2025 Earnings Call Transcript
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care
Exact sciences raises 2025 revenue guidance to $3.12B driven by Cologuard Plus launch

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。